MAP2K7 and melanoma: The systemic treatment landscape for advanced (i.e. unresectable stage IIIc or IV) melanoma patients has dramatically changed in recent years with the introduction of immunotherapies (CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF- and MEK-inhibitors) [1].